Tianyin Pharmaceutical Co. (TPI) 0.64 $TPI
JCM Plans for FDA certification Process for International Business Development
PR Newswire - Tue Feb 17, 1:55PM CST
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) updated on the business and development at its Jiangchuan Macrolide Facility (JCM) API operation.
TPI: 0.64 (+0.05)
TPI to Form Strategic Alliance with Buchang Pharma
PR Newswire - Fri Feb 06, 9:53AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that TPI and Buchang Pharmaceutical Co., Ltd. ("Buchang Pharma", http://www.bloomberg.com/profiles/companies/S...ls-co-ltd) plan to establish Tianyin-Buchang Strategic Alliance (the "Alliance"
to synergize and accelerate the growth of the Company, boosting TPI's mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL).
TPI: 0.64 (+0.05)
TPI's JCM Updates on Import Registration for International Clients
PR Newswire - Fri Jan 23, 2:03AM CST
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the business and development progress at its Jiangchuan Macrolide Facility (JCM) API operation.
TPI: 0.64 (+0.05)
TPI QLF Received GMP Certification
PR Newswire - Tue Jan 20, 6:30AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the TPI's Qionglai Tianyin Facility (QLF) has received its Good Manufacturing Practice (GMP) certificate from the China Food & Drug Administration's (CFDA) with the GMP certification processing number: SC20140067. The latest GMP certification has improved significantly regarding the level of stringency, standardization, quality control and etc and the receipt of the new GMP status is regarded a prominent advantage for the future growth of a pharmaceutical enterprise.
TPI: 0.64 (+0.05)
TPI Initiates the Official Relocation Process to Qionglai Tianyin Facility (QLF)
PR Newswire - Mon Jan 12, 10:50AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced the official start of the relocation procedure from the Company's original Longquan Facility to its Qionglai Tianyin Facility (QLF), expecting the imminent Good Manufacturing Practice (GMP) certification following TPI's completion of Public Notice (Gong Shi) Status for its QLF from the China Food & Drug Administration (CFDA) (http://www.scfda.gov.cn/directory/web/WS19/CL2076/96334.html). The pictures of the QLF can be viewed on the front page of Company's website: www.tianyinpharma.com
TPI: 0.64 (+0.05)
TPI QLF To Receive GMP Certification
PR Newswire - Thu Jan 08, 7:30AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company has successfully completed Public Notice (Gong Shi) Status for its Good Manufacturing Practice (GMP) certification of TPI's Qionglai Facility (QLF) from the China Food & Drug Administration's (CFDA) with the link at http://www.scfda.gov.cn/directory/web/WS19/CL2076/96334.html. GMP certification processing number: SC20140067. Upon the submission of the final round of documentation, TPI expects to receive GMP certification within five business days. The stringency of the latest GMP certification has improved significantly regarding the level of procedural documentation, standardization, quality control and etc. The receipt of the GMP status at TPI's QLF is regarded as a milestone for the future growth of the Company.
TPI: 0.64 (+0.05)
Buchang Pharmaceutical Visits Tianyin Qionglai Facility
PR Newswire - Tue Jan 06, 5:36AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announces that Buchang Pharmaceutical's management visited TPI's Qionglai Facility (QLF) and met with Tianyin's CEO. Buchang Pharmaceutical is one of the most distinguished enterprises in mTCM pharmaceutical manufacturing and distribution with a strong cardiovascular focus.
TPI: 0.64 (+0.05)
Week In Review: 2014 Pharma IPOs In China - Just 3
ChinaBio Today - at Seeking Alpha - Sun Jan 04, 4:46AM CST
Deals and Financings 2014 was supposed to be a breakout year for China life science IPOs. As the year began, China was all set to resume IPOs after a 15-month moratorium, with a new regulatory system and significant pent-up demand. But, for the...
TPI: 0.64 (+0.05), KANG: 17.00 (unch), WX: 40.70 (+0.48)
TPI Updates on Alliance Discussion
PR Newswire - Fri Jan 02, 10:42AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates regarding the Alliance discussions with industrial leaders (private and state-owned enterprises) in China's pharmaceutical market to form integrated platform of its mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL).
TPI: 0.64 (+0.05)
TPI in Talks with Well Capitalized Strategic Partner to Form Alliance to Build Nationwide Platform
PR Newswire - Fri Dec 26, 7:00AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company is engaged in discussion with a pharmaceutical industry strategic partner to form an Alliance (the "Alliance" in building a nationwide mTCM portfolio platform. We expect the Alliance to be based at TPI's new Qionglai Tianyin Facility (QLF) as the core entity with TPI's current product portfolio to drive the growth of the Company with a more focused effort to TPI's core product portfolio, an expanded national footprint and the opportunity to integrate both the upstream and downstream client base.
TPI: 0.64 (+0.05)
TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results
PR Newswire - Wed Dec 24, 4:36PM CST
CHENGDU, China, Dec. 24, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) released unaudited preliminary financial results for the first quarter of fiscal year 2015.
TPI: 0.64 (+0.05)
TPI QLF Achieved Public Notice Status of GMP Certification
PR Newswire - Tue Dec 23, 2:16PM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company achieved the Public Notice (Gong Shi) Status for its Good Manufacturing Practice (GMP) certificate of TPI's Qionglai Facility (QLF) from the China Food & Drug Administration's (CFDA). The public notice period is a significant procedure of GMP certification during which the pharmaceutical manufacturing facility's GMP application will be disclosed on the CFDA website (http://www.scfda.gov.cn/directory/web/WS19/CL2076/96334.html; GMP certification processing number: SC20140067). The public notice period lasts for approximately 10 business days which is to be followed by immediate issuance of the GMP certificate. TPI is currently preparing for the transition of production capacity from the current Longquan facilities to the new QLF immediately following the official issuance of GMP certificate.
TPI: 0.64 (+0.05)
TPI New Qionglai Facility (QLF) Updates
PR Newswire - Thu Dec 18, 9:54AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updated that the pictures of TPI's Qionglai Facility (QLF) are available on the front page of www.tianyinpharma.com. For additional information, please email ir@tpi.asia
TPI: 0.64 (+0.05)
TPI anticipates GMP certificate by end of December 2014
M2 - Wed Dec 17, 8:04AM CST
Pharmaceutical company Tianyin Pharmaceutical Co (NYSE MKT:TPI) disclosed on Tuesday that it expects to receive the formal Good Manufacturing Practice (GMP) certificate for its Qionglai Facility (QLF) from the China Food & Drug Administration's (CFDA) by the end of December 2014.
TPI: 0.64 (+0.05)
TPI Expects Receiving GMP by the end of December 2014
PR Newswire - Tue Dec 16, 12:54PM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates that it expects to receive the formal Good Manufacturing Practice (GMP) certificate for its Qionglai Facility's (QLF) from the China Food & Drug Administration's (CFDA) by the end of December 2014. Prior to the official issuance of the GMP certificate, there is a public notice period which is likely to take place within this week. The public notice period is an important step of GMP certificate during which the pharmaceutical manufacturing facility's GMP application will be disclosed on the CFDA website. The public notice time will last for approximately 10 business days which is to be followed by immediate issuance of the GMP certificate. TPI is currently preparing for the smooth transition of production capacity from the current Longquan facilities to the new QLF immediately following the official issuance of GMP certificate.
TPI: 0.64 (+0.05)
TPI in Talk with Industrial Leaders on Alliance to Boost Revenue for 2015
PR Newswire - Mon Dec 15, 4:22PM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates regarding discussions with industrial leaders in China's pharmaceutical market to form a potential alliance with the goal to boost revenue for the coming year. In recent years, TPI has made an effort to develop the network organically, yet met challenges due to price competition amid the current healthcare reforms in China. The Company recognizes the revenue decline for the fiscal year 2014 and that to expedite the process of revenue recovery, it is necessary to optimize sales strategies and to ally with well-entrenched industrial leaders to synergize various resources with emphasis on the width and depth of sales networks. The Company hopes the potential alliances could significantly increase core product portfolio sales with positive gross margin trends. The Company will provide prompt updates when these efforts substantiate.
TPI: 0.64 (+0.05)
TPI Reports Fiscal Year 2014 Financial Results
PR Newswire - Wed Dec 10, 3:38PM CST
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2014.
TPI: 0.64 (+0.05)
TPI Updates on its New Facility GMP Certification Progress and Growth Strategies
PR Newswire - Tue Dec 02, 6:00AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates that its Qionglai Facility's (QLF) Good Manufacturing Practice (GMP) certification to be issued by the China Food & Drug Administration's (CFDA) is expected to receive the status of public notice period within the month of December. The public notice period is a required procedure of GMP certification during which the pharmaceutical manufacturing facility's GMP application will be disclosed on the CFDA website. The public notice time will last for approximately 10 business days which could be followed by immediate issuance of the GMP certificate. TPI is currently preparing for the smooth transition of production capacity from the current Longquan facilities to the new QLF immediately following the official issuance of GMP certificate.
TPI: 0.64 (+0.05)
JCM Plans for FDA certification Process for International Business Development
PR Newswire - Tue Feb 17, 1:55PM CST
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) updated on the business and development at its Jiangchuan Macrolide Facility (JCM) API operation.
TPI: 0.64 (+0.05)
TPI to Form Strategic Alliance with Buchang Pharma
PR Newswire - Fri Feb 06, 9:53AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that TPI and Buchang Pharmaceutical Co., Ltd. ("Buchang Pharma", http://www.bloomberg.com/profiles/companies/S...ls-co-ltd) plan to establish Tianyin-Buchang Strategic Alliance (the "Alliance"
to synergize and accelerate the growth of the Company, boosting TPI's mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL). TPI: 0.64 (+0.05)
TPI's JCM Updates on Import Registration for International Clients
PR Newswire - Fri Jan 23, 2:03AM CST
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the business and development progress at its Jiangchuan Macrolide Facility (JCM) API operation.
TPI: 0.64 (+0.05)
TPI QLF Received GMP Certification
PR Newswire - Tue Jan 20, 6:30AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the TPI's Qionglai Tianyin Facility (QLF) has received its Good Manufacturing Practice (GMP) certificate from the China Food & Drug Administration's (CFDA) with the GMP certification processing number: SC20140067. The latest GMP certification has improved significantly regarding the level of stringency, standardization, quality control and etc and the receipt of the new GMP status is regarded a prominent advantage for the future growth of a pharmaceutical enterprise.
TPI: 0.64 (+0.05)
TPI Initiates the Official Relocation Process to Qionglai Tianyin Facility (QLF)
PR Newswire - Mon Jan 12, 10:50AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced the official start of the relocation procedure from the Company's original Longquan Facility to its Qionglai Tianyin Facility (QLF), expecting the imminent Good Manufacturing Practice (GMP) certification following TPI's completion of Public Notice (Gong Shi) Status for its QLF from the China Food & Drug Administration (CFDA) (http://www.scfda.gov.cn/directory/web/WS19/CL2076/96334.html). The pictures of the QLF can be viewed on the front page of Company's website: www.tianyinpharma.com
TPI: 0.64 (+0.05)
TPI QLF To Receive GMP Certification
PR Newswire - Thu Jan 08, 7:30AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company has successfully completed Public Notice (Gong Shi) Status for its Good Manufacturing Practice (GMP) certification of TPI's Qionglai Facility (QLF) from the China Food & Drug Administration's (CFDA) with the link at http://www.scfda.gov.cn/directory/web/WS19/CL2076/96334.html. GMP certification processing number: SC20140067. Upon the submission of the final round of documentation, TPI expects to receive GMP certification within five business days. The stringency of the latest GMP certification has improved significantly regarding the level of procedural documentation, standardization, quality control and etc. The receipt of the GMP status at TPI's QLF is regarded as a milestone for the future growth of the Company.
TPI: 0.64 (+0.05)
Buchang Pharmaceutical Visits Tianyin Qionglai Facility
PR Newswire - Tue Jan 06, 5:36AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announces that Buchang Pharmaceutical's management visited TPI's Qionglai Facility (QLF) and met with Tianyin's CEO. Buchang Pharmaceutical is one of the most distinguished enterprises in mTCM pharmaceutical manufacturing and distribution with a strong cardiovascular focus.
TPI: 0.64 (+0.05)
Week In Review: 2014 Pharma IPOs In China - Just 3
ChinaBio Today - at Seeking Alpha - Sun Jan 04, 4:46AM CST
Deals and Financings 2014 was supposed to be a breakout year for China life science IPOs. As the year began, China was all set to resume IPOs after a 15-month moratorium, with a new regulatory system and significant pent-up demand. But, for the...
TPI: 0.64 (+0.05), KANG: 17.00 (unch), WX: 40.70 (+0.48)
TPI Updates on Alliance Discussion
PR Newswire - Fri Jan 02, 10:42AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates regarding the Alliance discussions with industrial leaders (private and state-owned enterprises) in China's pharmaceutical market to form integrated platform of its mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL).
TPI: 0.64 (+0.05)
TPI in Talks with Well Capitalized Strategic Partner to Form Alliance to Build Nationwide Platform
PR Newswire - Fri Dec 26, 7:00AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company is engaged in discussion with a pharmaceutical industry strategic partner to form an Alliance (the "Alliance"
in building a nationwide mTCM portfolio platform. We expect the Alliance to be based at TPI's new Qionglai Tianyin Facility (QLF) as the core entity with TPI's current product portfolio to drive the growth of the Company with a more focused effort to TPI's core product portfolio, an expanded national footprint and the opportunity to integrate both the upstream and downstream client base. TPI: 0.64 (+0.05)
TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results
PR Newswire - Wed Dec 24, 4:36PM CST
CHENGDU, China, Dec. 24, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) released unaudited preliminary financial results for the first quarter of fiscal year 2015.
TPI: 0.64 (+0.05)
TPI QLF Achieved Public Notice Status of GMP Certification
PR Newswire - Tue Dec 23, 2:16PM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company achieved the Public Notice (Gong Shi) Status for its Good Manufacturing Practice (GMP) certificate of TPI's Qionglai Facility (QLF) from the China Food & Drug Administration's (CFDA). The public notice period is a significant procedure of GMP certification during which the pharmaceutical manufacturing facility's GMP application will be disclosed on the CFDA website (http://www.scfda.gov.cn/directory/web/WS19/CL2076/96334.html; GMP certification processing number: SC20140067). The public notice period lasts for approximately 10 business days which is to be followed by immediate issuance of the GMP certificate. TPI is currently preparing for the transition of production capacity from the current Longquan facilities to the new QLF immediately following the official issuance of GMP certificate.
TPI: 0.64 (+0.05)
TPI New Qionglai Facility (QLF) Updates
PR Newswire - Thu Dec 18, 9:54AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updated that the pictures of TPI's Qionglai Facility (QLF) are available on the front page of www.tianyinpharma.com. For additional information, please email ir@tpi.asia
TPI: 0.64 (+0.05)
TPI anticipates GMP certificate by end of December 2014
M2 - Wed Dec 17, 8:04AM CST
Pharmaceutical company Tianyin Pharmaceutical Co (NYSE MKT:TPI) disclosed on Tuesday that it expects to receive the formal Good Manufacturing Practice (GMP) certificate for its Qionglai Facility (QLF) from the China Food & Drug Administration's (CFDA) by the end of December 2014.
TPI: 0.64 (+0.05)
TPI Expects Receiving GMP by the end of December 2014
PR Newswire - Tue Dec 16, 12:54PM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates that it expects to receive the formal Good Manufacturing Practice (GMP) certificate for its Qionglai Facility's (QLF) from the China Food & Drug Administration's (CFDA) by the end of December 2014. Prior to the official issuance of the GMP certificate, there is a public notice period which is likely to take place within this week. The public notice period is an important step of GMP certificate during which the pharmaceutical manufacturing facility's GMP application will be disclosed on the CFDA website. The public notice time will last for approximately 10 business days which is to be followed by immediate issuance of the GMP certificate. TPI is currently preparing for the smooth transition of production capacity from the current Longquan facilities to the new QLF immediately following the official issuance of GMP certificate.
TPI: 0.64 (+0.05)
TPI in Talk with Industrial Leaders on Alliance to Boost Revenue for 2015
PR Newswire - Mon Dec 15, 4:22PM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates regarding discussions with industrial leaders in China's pharmaceutical market to form a potential alliance with the goal to boost revenue for the coming year. In recent years, TPI has made an effort to develop the network organically, yet met challenges due to price competition amid the current healthcare reforms in China. The Company recognizes the revenue decline for the fiscal year 2014 and that to expedite the process of revenue recovery, it is necessary to optimize sales strategies and to ally with well-entrenched industrial leaders to synergize various resources with emphasis on the width and depth of sales networks. The Company hopes the potential alliances could significantly increase core product portfolio sales with positive gross margin trends. The Company will provide prompt updates when these efforts substantiate.
TPI: 0.64 (+0.05)
TPI Reports Fiscal Year 2014 Financial Results
PR Newswire - Wed Dec 10, 3:38PM CST
Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2014.
TPI: 0.64 (+0.05)
TPI Updates on its New Facility GMP Certification Progress and Growth Strategies
PR Newswire - Tue Dec 02, 6:00AM CST
Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today updates that its Qionglai Facility's (QLF) Good Manufacturing Practice (GMP) certification to be issued by the China Food & Drug Administration's (CFDA) is expected to receive the status of public notice period within the month of December. The public notice period is a required procedure of GMP certification during which the pharmaceutical manufacturing facility's GMP application will be disclosed on the CFDA website. The public notice time will last for approximately 10 business days which could be followed by immediate issuance of the GMP certificate. TPI is currently preparing for the smooth transition of production capacity from the current Longquan facilities to the new QLF immediately following the official issuance of GMP certificate.
TPI: 0.64 (+0.05)
